OSR Holdings, Inc. (OSR), a company operating within the Health Care sector, has recently garnered attention due to a Nasdaq extension granted on March 5, 2026. This extension, which spans a 180-day period, underscores the company’s commitment to maintaining its market presence. As of the latest trading session on March 8, 2026, OSR’s stock closed at $0.502. This price is notably modest when compared to its 52-week high of $4.33, achieved on March 25, 2025, and its 52-week low of $0.38, recorded on March 2, 2026.
OSR Holdings, Inc. is identified as Bellevue Life Sciences Acquisition Corp., a blank check company based in the United States. The primary objective of OSR is to acquire one or more businesses and assets through various means, including mergers, capital stock exchanges, asset acquisitions, stock purchases, and reorganizations.
From a financial perspective, OSR’s stock is currently trading at a price-to-earnings (P/E) ratio of -0.29, indicating negative earnings. Additionally, the price-to-book (P/B) ratio stands at 0.133, suggesting that the stock is valued well below its book value. These metrics highlight a highly discounted equity position relative to both earnings and assets. This valuation is consistent with the company’s recent market volatility and the temporary nature of its Nasdaq listing extension.
With a market capitalization of $13,180,410 USD, OSR Holdings, Inc. continues to navigate the complexities of the health care sector while striving to achieve its acquisition objectives. The company’s strategic focus on mergers and acquisitions positions it uniquely within the market, despite the challenges reflected in its current financial metrics.
